Table 2.

MERS infection and maternal–fetal outcome.

Country	Cases	Maternal		Newborn
		Complication	MERS-CoV antibody	Delivery	Complication	MERS-CoV antibody
Saudi Arabia	1	Asymptomatic	Nasopharyngeal (+)	Term NSD	No Adverse Effects	X
	2	Asymptomatic	Nasopharyngeal (+)	Term NSD	No Adverse Effects	X
	3	Lung infiltration s/p antibiotics	Nasopharyngeal (+)	34 weeks Induction	IUFD	X
	4	MERS Fatality	Nasopharyngeal (+)	38 weeks NSD	No Adverse Effects	X
	5	MERS Fatality	Nasopharyngeal (+)	24 weeks Cesarean Maternal Hypoxia	Preterm Expire	X
	6	Lung infiltration s/p antibiotics	Nasopharyngeal (+)	Term NSD	No Adverse Effect	X
	7	Progressive Lung Infiltration s/p Mechanical Ventilation	Nasopharyngeal (+)	Term NSD	No Adverse Effect	X
	8	Progressive Lung Infiltration s/p Mechanical Ventilation	Nasopharyngeal (+)	32 weeks Cesarean Maternal Hypoxia	No Adverse Effect	X
Jordan	1	Refuse treatment	EIA (+)	20 weeks Induction	IUFD	X
United Arab Emirates	1	MERS Fatality	Nasopharyngeal (−) RT-PCR (+)	32 weeks Cesarean Maternal Hypoxia	No Adverse Effects	X
South Korea	1	Lung infiltration s/p antibiotics	RT-PCR (+)	37 + 5 weeks Cesarean Placenta abruption	No Adverse Effects	Cord blood (−) Placenta (−)